Effect of cevimeline on salivary components in patients with Sjögren syndrome

Pharmacology

Volumn 74, Issue 2, 2005, Pages 100-105

  Suzuki, Kimihiro ^a   Matsumoto, Mitsuyo ^a   Nakashima, Masahiro ^a   Takada, Kunio ^a   Nakanishi, Takashi ^a   Okada, Makoto ^a   Ohsuzu, Fumitaka ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Cevimeline; Muscarinic receptors; Salivary amylase; Sicca syndrome

Indexed keywords

AMYLASE; CEVIMELINE; IMMUNOGLOBULIN A; LYSOZYME; SQUAMOUS CELL CARCINOMA ANTIGEN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM; DOSE RESPONSE; DRUG EFFICACY; ENZYME RELEASE; FEMALE; FREQUENCY ANALYSIS; HUMAN; IMMUNITY; PRIORITY JOURNAL; SALIVA; SALIVATION; SJOEGREN SYNDROME; STATISTICAL SIGNIFICANCE;

ALPHA-AMYLASE; ANTIGENS, NEOPLASM; FEMALE; HUMANS; IMMUNOGLOBULIN A; MIDDLE AGED; MURAMIDASE; MUSCARINIC AGONISTS; QUINUCLIDINES; SALIVA; SALIVATION; SERPINS; SJOGREN'S SYNDROME; THIOPHENES; XEROSTOMIA;

EID: 20444486541     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084031     Document Type: Article

References (31)

1. Fox RI, Stern M, Michelson P: Update in Sjögren syndrome. Curr Opin Rheumatol 2000;12:391-398.
2. Dawes C: Factors influencing salivary flow rate and composition; in Edger WM, O'Mullane DM (eds): Saliva and Oral Health, ed 2. London, BDJ Books, 1996, pp 27-41.
3. Pillimer S: Sjögren syndrome; in Klippel JH (ed): Primer on the Rheumatic Diseases, ed 12. Atlanta, Arthritis Foundation, 2001, pp 377-383.
4. Hamilton SE, Schlador ML, McKinnon LA, Chmelar RS, Nathanson NM: Molecular mechanisms for the regulation of the expression and function of muscarinic acetylcholine receptors. J Physiol Paris 1998;92:275-278.
5. Mei L, Roeske WR, Izutsu KT, Yamamura HI: Characterization of muscarinic acetylcholine receptors in human labial salivary glands. Eur J Pharmacol 1990;176:367-370.
6. Dai YS, Ambudkar IS, Horn VJ, Yeh CK, Kousvelari EE, Wall SJ, Li M, Yasuda RP, Wolfe BB, Baum BJ: Evidence that M3 muscarinic receptors in rat parotid gland couple to two second messenger systems. Am J Physiol 1991;261:C1063-C1073.
7. Iwabuchi Y, Masuhara T: Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: Identification of a potential therapeutic agent for treatment of Sjörgen's syndrome. Gen Pharmacol 1994;25:123-129.
8. Daiichi Pharmaceutical Co., Ltd: Effects of cevimeline on the intracellular signaling pathway after stimulating M1, M2, M3, M4, or M5 muscarinic receptors expressed on the CHO-K1 cells. Interview form for Evoxac capsules 30 mg, 2002, p 12 (in Japanese).
9. Yasuda H, Niki H: Review of the pharmacological properties and clinical usefulness of muscarine agonists for xerostomia in patients with Sjögren's syndrome. Clin Drug Invest 2002;22:67-73.
10. Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P: A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum 2002;46:748-754.
11. Fife RS, Chase WF, Dore RK, Wiesenhutter CW, Lockhart PB, Tindall, E, Suen JY: Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: A randomized trial. Arch Intern Med 2002;162:1293-1300.
12. Kashiwazaki S, Okano Y, Miyawaki S: Pharmacokinetics and salivation effect of the single dose of SNI-2011 in patients with Sjögren's syndrome (in Japanese). Shinryo to Shinyaku 2001;38:81-93.
13. Masunaga H, Ogawa H, Uematsu Y, Tomizuka T, Yasuda H, Takeshita Y: Long-lasting salivation induced by a novel muscarinic receptor agonist SNI-2011 in rats and dogs. Eur J Pharmacol 1997;339:1-9.
14. Hay DI, Brown WH: The functions of salivary proteins; in Edger WM, O'Mullane DM (eds): Saliva and Oral Health, ed 2. London, BDJ Books, 1996, pp 105-122.
15. Raj PA, Edgerton M, Levine MJ: Salivary histatin 5: Dependence of sequence, chain length, and helical conformation for candidacidal activity. J Biol Chem 1990;265:3898-3905.
16. Murphy RA, Pantazis NJ, Papastavros M: Epidermal growth factor and nerve growth factor in mouse saliva: A comparative study. Dev Biol 1979;71:356-370.
17. Yuan Z, Iida H, Inoue N, Ishikawa Y, Ishida H: Effect of SNI-2011 on amylase secretion from parotid tissue in rats and in neuronal nitric oxide synthase knockout mice. Eur J Pharmacol 2003;464:197-206.
18. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH: Classification criteria for Sjögren's syndrome: A revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-558.
19. Ishikawa Y, Ishida H: Aquaporin water channel in salivary glands. Jpn J Pharmacol 2000; 83:95-101.
20. Gresz V, Kwon TH, Hurley PT, Varga G, Zelles T, Nielsen S, Case RM, Steward MC: Identification and localization of aquaporin water channels in human salivary glands. Am J Physiol Gastrointest Liver Physiol 2001;281: G247-G254.
21. Ishikawa Y, Skowronski MT, Ishida H: Persistent increase in the amount of aquaporin-5 in the apical plasma membrane of rat parotid acinar cells induced by a muscarinic agonist SNI-2011. FEBS Lett 2000;477:253-257.
22. Fabian TK, Gaspar J, Fejerdy L, Kaan B, Balint M, Csermely P, Fejerdy P: Hsp70 is present in human saliva. Med Sci Monit 2003; 9:BR62-BR65.
23. Nagy A, Barta A, Varga G, Zelles T: Changes of salivary amylase in serum and parotid gland during pharmacological and physiological stimulation. J Physiol Paris 2001;95:141-145.
24. Torre GC: SCC antigen in malignant and non-malignant squamous lesions. Tumour Biol 1998;19:517-526.
25. Ravald N, List T: Caries and periodontal conditions in patients with primary Sjögren's syndrome. Swed Dent J 1998;22:97-103.
26. Christensen LB, Petersen PE, Thorn JJ, Schiodt M: Dental caries and dental health behavior of patients with primary Sjögren syndrome. Acta Odontol Scand 2001;59:116-120.
27. Najera MP, al-Hashimi I, Plemons JM, Rivera-Hidalgo F, Rees TD, Haghighat N, Wright JM: Prevalence of periodontal disease in patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997;83: 453-457.
28. Soto-Rojas AE, Villa AR, Sifuentes-Osornio J, Alarcon-Segovia D, Kraus A: Oral candidiasis and Sjögren's syndrome. J Rheumatol 1998; 25:911-915.
29. Abraham CM, al-Hashimi I, Haghighat N: Evaluation of the levels of oral Candida in patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;86: 65-68.
30. Beck JD, Offenbacher S, Williams R, Gibbs P, Garcia R: Periodontitis: A risk factor for coronary heart disease? Ann Periodontol 1998;3: 127-141.
31. Shay K: Infectious complications of dental and periodontal diseases in the elderly population. Clin Infect Dis 2002;34:1215-1223.